

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

27 June 2024

## **Genflow Biosciences Plc**

### **Genflow Biosciences Strengthens Pre-Clinical Efforts with FDA Guidance and CDMO and CRO Selection**

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to report advancements in its pre-clinical programs.

Genflow has initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP).

Genflow is also in the process of selecting Contract Research Organizations (CROs) to conduct its upcoming dog clinical trial, aimed at studying its promising drug candidate, GF-1004. The Company is currently evaluating requests for proposals (RFPs) and is working diligently to finalize a definitive agreement next month.

In addition, Genflow has received research guidance from the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT). The Company submitted a comprehensive briefing package detailing all preclinical (in vitro and in vivo) studies conducted with its lead drug candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH).

The FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (POC) studies. These studies will inform the definitive POC, toxicology, and biodistribution studies necessary for eventual clinical trials. Detailed summaries of the products used in each animal study and their comparability to the intended clinical product are to be included.

Dr. Eric Leire, CEO of Genflow commented: " We are excited by the momentum we have built in moving forward with our pre-clinical programs and the guidance received from the FDA. This encouragement reinforces our commitment to developing effective therapeutic solutions for age-related diseases. As we move forward with our dog clinical trials, we remain focused on our mission to improve healthspan."

## **Contacts**

### **Genflow Biosciences**

Dr Eric Leire, CEO  
+32-477-495-881

### **Harbor Access**

Jonathan Paterson, Investor Relations  
+1 475 477 9401  
Jonathan.Paterson@Harbor-access.com

Joint Corporate Brokers  
**Capital Plus Partners Ltd**  
Keith Swann, +44 0203 821 6169  
Jon Critchley, +44 0203 821 6168

## **About Genflow Biosciences**

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit [www.genflowbio.com](http://www.genflowbio.com) and follow the Company on LinkedIn and Twitter/X.

## **DISCLAIMER**

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAKZGZVKVFGDZM